慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究*

doi:10.3969/j.issn.1672-5069.2019.06.0010

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (6): 816-819.doi: 10.3969/j.issn.1672-5069.2019.06.0010

慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*

朱凌云, 张茂海, 崔莎莎, 张秋萍

435100湖北理工学院第三附属医院/湖北省大冶市人民医院检验科（朱凌云,张茂海）; 襄阳市中医医院检验科（崔莎莎）; 武汉大学基础医学院免疫学教研室（张秋萍）

收稿日期:2019-01-23 出版日期:2019-11-13 发布日期:2019-11-13
通讯作者: 崔莎莎,E-mail: 379952219@qq.com
作者简介:朱凌云,女,34岁,硕士研究生,主管技师。主要从事免疫学检验研究。E-mail: 414457748@qq.com
基金资助:
湖北省自然科学基金资助项目（编号：2018962）

Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with

chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.

Clinical Laboratory,Third Affiliated Hospital,Hubei Institute of Technology,Daye 435100,Hubei Province,China

Received:2019-01-23 Online:2019-11-13 Published:2019-11-13

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎（CHB）患者血清白细胞介素-12（IL-12）、IL-18和外周血单个核细胞叉头蛋白P3（Foxp3）基因水平变化及其临床意义。方法 2015年7月~2018年3月我院收治的CHB患者78例和同期健康体检者25例,采用ELISA法检测血清IL-12和IL-18水平,分离外周血单个核细胞,采用RT-PCR法检测细胞Foxp3 mRNA水平。结果在78例CHB患者中,经肝组织活检诊断G1组21例,G2组24例,G3组19例,G4组14例;CHB患者血清ALT和AST水平分别为（278.3±89.4）U/L和（305.3±84.6） U/L,显著高于健康人的[（25.3±7.6） U/L和（20.3±6.5） U/L,P<0.05];G4组血清ALT和AST水平分别为（563.5±132.4） U/L和（513.3±102.5） U/L,显著高于G1组[（113.2±67.4）U/L和（73.5±25.3） U/L]或G2组[（153.6±45.3） U/L和（113.8±35.2） U/L]或G3组[（240.5±56.6） U/L和（156.7±51.2） U/L,P<0.05];CHB患者血清IL-12和IL-18水平及单个核细胞Foxp3 mRNA水平分别为（198.3±19.6） pg/ml、（408.6±91.2） pg/ml及（4.5±0.7）,显著高于健康人[（64.5±10.9） pg/ml、（127.3±15.7） pg/ml、（3.3±0.4）,P<0.05];G4组血清IL-12、IL-18及Foxp3基因水平分别为（237.5±23.6） pg/ml、（431.5±106.3） pg/ml、（5.1±0.3）],显著高于G1组[（146.3±15.2） pg/ml、（390.2±90.3） pg/ml、（3.7±0.6）] 或G2组[（185.2±13.6） pg/ml、（403.6±93.2） pg/ml、（3.9±0.5） pg/ml]或G3组[（203.2±18.3）pg/ml、（414.3±105.4） pg/ml、（4.3±0.7）,P<0.05]。结论 CHB患者外周血单个核细胞Foxp3基因及血清IL-12和IL-18水平显著升高,且肝组织炎症活动显著者,其水平更高,提示其参与了CHB的发病过程。及时检测这些指标可能对监测病情变化和判断治疗应答有帮助。

关键词: 慢性乙型肝炎, 白细胞介素-12, 白细胞介素-18, 叉头蛋白P3

Abstract: Objective The aim of this study was to explore the changes of serum IL-12 （IL-12） and IL-18 levels as well as peripheral blood mononuclear cell（PBMCs） forkhead/winged helix transcription factor （FOXp3） in patients with chronic hepatitis B（CHB）. Methods 78 patients with CHB and 25 healthy persons were recruited in our hospital,and all patients received liver biopsies. Serum IL-12 and IL-18 levels were detected by ELISA,and Foxp3 mRNA from PBMCs were assayed by RT-PCR. Results Out of the 78 patients with CHB,21 cases were found with G1,24 cases in G2,19 cases in G3 and 14 cases in G4 by histopathological examination;serum ALT and AST levels in patients with CHB were（278.3±89.4） U/L and（305.3±84.6） U/L,significantly higher than [（25.3±7.6） U/L and （20.3±6.5） U/L,P<0.05] in healthy control;serum level of ALT and AST in G4 group were （563.5±132.4） U/L and （513.3±102.5） U/L,significantly higher than [（113.2±67.4） U/L and （73.5±25.3） U/L in G1 group] or [（153.6 ±45.3） U/L and （113.8 ±35.2） U/L in G2 group] or [（240.5±56.6） U/L and（156.7±51.2） U/L in G3 group,P<0.05];serum IL-12 and IL-18 as well as PBMC Foxp3 in patients with CHB were （198.3±19.6） pg/ml,（408.6±91.2） pg/ml and（4.5±0.7）,significantly higher than[（64.5±10.9） pg/ml,（127.3±15.7） pg/ml and（3.3±0.4）,P<0.05] in healthy individuals;serum IL-12,IL-18 and Foxp3 mRNA in G4 group were （237.5±23.6） pg/ml,（431.5±106.3） pg/ml and（5.1±0.3）,significantly higher than [（146.3±15.2） pg/ml],（390.2±90.3） pg/ml and （3.3±0.4）] in G1,[（185.2±13.6） pg/ml,（403.6±93.2） pg/ml and （3.9±0.5）] in G2 group,or [（203.2±18.3） pg/ml,（414.3±105.4） pg/ml and （4.3±0.7） P<0.05] in G3 group. Conclusion IL-12 and IL-18 might be involved in the pathogenesis of CHB,and early detection of IL-12,IL-18 and Foxp3 gene could be beneficial to predict the progress of the disease.

Key words: Chronic hepatitis B, Interleukin-12, Interleukin-18, Forkhead/winged helix transcription factor

朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.

chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with[J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.

参考文献

[1] Brock C,Yi Y,Papaluca T,et al.Exploring the feasibility of targeted chronic hepatitis B screening in the emergency department:A pilot study. Emerg Med Australas,2018,30(6):864-866.
[2] Tanaka A,Inaguma D,Watanabe Y,et al.Hepatitis B virus infection among patients with chronic kidney disease who attended an educational program in Japan. Ther Apher Dial,2018,22(6):588-593.
[3] Kawai K,Uchiyama M,Hester J.et al.Regulatory T cells for tolerance. Hum Immunol,2018,79(5):294-303.
[4] Bai X,Shi H,Yang M,et al.Identification of key genes implicated in the suppressive function of human FOXP3+CD25+CD4+ regulatory T cells through the analysis of time series data. Mol Med Rep,2018,17(3):647-3657.
[5] Schmidt A,Marabita F,Kiani NA,et al.Time-resolved transcriptome and proteome landscape of human regulatory T cell(Treg) differentiation reveals novel regulators of FOXP3. BMC Biol 2018,16(1):47.
[6] Hashemi V,Farrokhi AS,Tanomand A,et al.Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population. Immunol Lett,2018,20(4):16-22.
[7] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[8] 郑珍川,许夕海. 慢性乙型肝炎患者临床和肝组织病理学特点及影响肝纤维化因素分析. 实用肝脏病杂志,2018,21(5):713-716.
[9] Liu M,Li S,Li MO.TGF-β control of adaptive immune tolerance:A break from Treg cells. Bioessays,2018,40(11): e1800063.
[10] Leung CS,Yang KY,Li X,et al.Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. Genome Med,2018,10(1):71.
[11] Churlaud G,Abbara C,Vinot PA,et al. Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2. J Allergy ClinImmunol,2018,142(4):1344-1346.e3.
[12] Altmann DM.Regulatory T-cells:receptors,repertoires and roles in disease. Immunology,2018,155(2):153-154.
[13] Palacz M,Tremellen K.High body Mass index is associated with an expansion of endometrial T Regulatory cell and macrophage populations. J Reprod Immunol,2018,12(9):36-39.
[14] 张君,李风,范玉琛,等. 慢性乙型肝炎患者CD4+T细胞Foxp3基因甲基化状态的研究.中华实验和临床病毒学杂志,2018,32(1):32-37.
[15] 董令,张爱华,朱凯,等. CD4+CD25+Foxp3+调节性T细胞在砷暴露大鼠肝脏中的表达差异及意义.中华地方病学杂志,2018,37(2):96-101.
[16] Rojas J,Teran-Angel G,Barbosa L,et al.Activation-dependent mitochondrial translocation of Foxp3 in human hepatocytes. Exp Cell Res,2016,343(2):159-167.
[17] Shi JY,Ma LJ,Zhang JW,et al.FOXP3is a HCC suppressor gene and acts through regulating the TGF-β/Smad2/3 signaling pathway. BMC Cancer,2017,17(1):648.
[18] Ghosh S,Roy-Chowdhuri S,Kang K,et al.The transcription factor Foxp1 preserves integrity of an active Foxp3 locus in extrathymic Treg cells. Nat Commun,2018,9(1):4473.
[19] 叶明. 原发性肝癌患者血清IL-6、IL-18和IL-18BP检测的意义. 实用肝脏病杂志,2016,19(3):354-355.
[20] Jiang QQ,Han MF,Ma K,et al.Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol,2018,24(21):2300-2310.

慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*

Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[2]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[3]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[4]	张燕妮, 孙晓花, 何海燕, 杜芸芸, 韩慧. 腔镜肝门肠吻合术治疗新生儿胆道闭锁症疗效初步研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 920-923.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[7]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[10]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[11]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[14]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[15]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.